All transthyretin amyloidosis articles
-
NewsNew study explores therapeutic potential of CRISPRCas3 genome-editing system
Scientists working on the genetic disease transthyretin amyloidosis evaluated the efficacy of the CRISPR–Cas3 system in safely achieving a permanent reduction of transthyretin (TTR) production through genome editing of the TTR gene.